What is happening with scopus biopharma inc. stock today?

I’m not able to fetch real‑time market data, so I can’t give you the current price or intraday movement for Scopus Biopharma Inc. (ticker SBI, if it’s still listed).

What you can do instead

A quick snapshot (as of my last update in 2024)

• Business: Scopus Biopharma focused on developing small‑molecule therapeutics for oncology and rare diseases.
• Pipeline: The flagship candidate, SB‑101, entered Phase 2 trials for metastatic colorectal cancer (last disclosed in 2023).
• Funding: In 2023 the company closed a $50 m Series B, and had a $30 m operating runway through mid‑2025.
• Market status: The shares were thinly traded, with a market cap that hovered between $150 m–$200 m in 2024, and they were listed on the OTC market under the symbol “SBI” (not a Nasdaq/Nasdaq‑GS listing).

Typical factors that move the stock

1. Clinical milestones – Positive/negative data from Phase I/II/III studies often cause sharp swings.
2. Partnerships or licensing deals – Announcements of collaborations with larger pharma firms can lift the stock.
3. Regulatory filings – FDA approvals, IND approvals, or adverse comments can have a big impact.
4. Cash‑flow events – New equity rounds, debt issuances, or dividend declarations affect valuation.
5. Macro‑market conditions – Biotech stocks are highly sensitive to changes in risk appetite, interest rates, and broader market sentiment.

If you’re looking to make an investment decision, consider:

• Checking the most recent 8‑K or 10‑Q for any material events or changes in the business plan.
• Reviewing the current clinical status of SB‑101 and any other pipeline assets.
• Watching for any upcoming earnings releases – the company’s guidance can move the price significantly.
• Consulting a financial advisor to assess whether the risk profile fits your portfolio.

Let me know if you’d like a deeper dive into the company’s pipeline, financials (as of the last available filings), or historical performance. I’m happy to help!